327 related articles for article (PubMed ID: 32662532)
21. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
22. The association between the LRRK2 R1628P variant and the risk of Parkinson's disease in Asian: a meta-analysis.
Wang X; Zhang X; Xue L; Xie A
Neurosci Lett; 2016 Jun; 623():22-7. PubMed ID: 27133195
[TBL] [Abstract][Full Text] [Related]
23. Fatigue correlates with LRRK2 G2385R variant in Chinese Parkinson's disease patients.
Fu R; Cui SS; Du JJ; He YC; Gao C; Huang P; Qian YW; Luo XG; Chen SD
Parkinsonism Relat Disord; 2017 Nov; 44():101-105. PubMed ID: 28941828
[TBL] [Abstract][Full Text] [Related]
24. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
25. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
[TBL] [Abstract][Full Text] [Related]
26. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
27. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
28. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.
Li Y; Ikeda A; Yoshino H; Oyama G; Kitani M; Daida K; Hayashida A; Ogaki K; Yoshida K; Kimura T; Nakayama Y; Ito H; Sugeno N; Aoki M; Miyajima H; Kimura K; Ueda N; Watanabe M; Urabe T; Takanashi M; Funayama M; Nishioka K; Hattori N
J Hum Genet; 2020 Sep; 65(9):771-781. PubMed ID: 32398759
[TBL] [Abstract][Full Text] [Related]
29. Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
Cao M; Gu ZQ; Li Y; Zhang H; Dan XJ; Cen SS; Li DW; Chan P
Neurosci Bull; 2016 Dec; 32(6):572-576. PubMed ID: 27699718
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
31. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
[TBL] [Abstract][Full Text] [Related]
32. LRRK2-associated Parkinson's disease patients have better stereopsis than idiopathic Parkinson disease.
Sun L; Chan P
Clin Neurol Neurosurg; 2018 Jun; 169():174-177. PubMed ID: 29705653
[TBL] [Abstract][Full Text] [Related]
33. Connectivity of corticostriatal circuits in nonmanifesting LRRK2 G2385R and R1628P carriers.
Zhang D; Yao J; Ma J; Gao L; Sun J; Fang J; He H; Wu T
CNS Neurosci Ther; 2022 Dec; 28(12):2024-2031. PubMed ID: 35934920
[TBL] [Abstract][Full Text] [Related]
34. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
35. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
36. The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population.
Kim JM; Lee JY; Kim HJ; Kim JS; Shin ES; Cho JH; Park SS; Jeon BS
Parkinsonism Relat Disord; 2010 Feb; 16(2):85-8. PubMed ID: 19854095
[TBL] [Abstract][Full Text] [Related]
37. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
[TBL] [Abstract][Full Text] [Related]
38. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
[TBL] [Abstract][Full Text] [Related]
39. LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U; Tan EK
FEBS J; 2009 Nov; 276(22):6455-63. PubMed ID: 19804413
[TBL] [Abstract][Full Text] [Related]
40. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
